Please use this identifier to cite or link to this item: http://hdl.handle.net/1893/24350
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCollins, Ian-
dc.contributor.authorBickerstaffe, Adrian-
dc.contributor.authorRanaweera, Thilina-
dc.contributor.authorMaddumarachchi, Sanjaya-
dc.contributor.authorKeogh, Louise-
dc.contributor.authorEmery, Jon-
dc.contributor.authorMann, G Bruce-
dc.contributor.authorButow, Phyllis-
dc.contributor.authorWeideman, Prue-
dc.contributor.authorSteel, Emma-
dc.contributor.authorTrainer, Alison-
dc.contributor.authorBressel, Mathias-
dc.contributor.authorHopper, John L-
dc.contributor.authorCuzick, John-
dc.contributor.authorAntoniou, Antonis C-
dc.contributor.authorPhillips, Kelly-Anne-
dc.date.accessioned2018-01-20T05:29:05Z-
dc.date.available2018-01-20T05:29:05Z-
dc.date.issued2016-02-
dc.identifier.urihttp://hdl.handle.net/1893/24350-
dc.description.abstractWe aimed to develop a user-centered, web-based, decision support tool for breast cancer risk assessment and personalized risk management. Using a novel model choice algorithm, iPrevent® selects one of two validated breast cancer risk estimation models (IBIS or BOADICEA), based on risk factor data entered by the user. Resulting risk estimates are presented in simple language and graphic formats for easy comprehension. iPrevent® then presents risk-adapted, evidence-based, guideline-endorsed management options. Development was an iterative process with regular feedback from multidisciplinary experts and consumers. To verify iPrevent®, risk factor data for 127 cases derived from the Australian Breast Cancer Family Study were entered into iPrevent®, IBIS (v7.02), and BOADICEA (v3.0). Consistency of the model chosen by iPrevent® (i.e., IBIS or BOADICEA) with the programmed iPrevent® model choice algorithm was assessed. Estimated breast cancer risks from iPrevent® were compared with those attained directly from the chosen risk assessment model (IBIS or BOADICEA). Risk management interventions displayed by iPrevent® were assessed for appropriateness. Risk estimation model choice was 100% consistent with the programmed iPrevent®logic. Discrepant 10-year and residual lifetime risk estimates of >1% were found for 1 and 4 cases, respectively, none was clinically significant (maximal variation 1.4%). Risk management interventions suggested by iPrevent® were 100% appropriate. iPrevent® successfully integrates the IBIS and BOADICEA risk assessment models into a decision support tool that provides evidence-based, risk-adapted risk management advice. This may help to facilitate precision breast cancer prevention discussions between women and their healthcare providers.en_UK
dc.language.isoen-
dc.publisherSpringer-
dc.relationCollins I, Bickerstaffe A, Ranaweera T, Maddumarachchi S, Keogh L, Emery J, Mann GB, Butow P, Weideman P, Steel E, Trainer A, Bressel M, Hopper JL, Cuzick J, Antoniou AC & Phillips K (2016) iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management, Breast Cancer Research and Treatment, 156 (1), pp. 171-182.-
dc.rights© The Author(s) 2016 This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.-
dc.subjectBreast canceren_UK
dc.subjectRisken_UK
dc.subjectDecision supporten_UK
dc.subjectBRCA1en_UK
dc.subjectChemopreventionen_UK
dc.titleiPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and managementen_UK
dc.typeJournal Articleen_UK
dc.identifier.doihttp://dx.doi.org/10.1007/s10549-016-3726-y-
dc.identifier.pmid26909793-
dc.citation.jtitleBreast Cancer Research and Treatment-
dc.citation.issn0167-6806-
dc.citation.volume156-
dc.citation.issue1-
dc.citation.spage171-
dc.citation.epage182-
dc.citation.publicationstatusPublished-
dc.citation.peerreviewedRefereed-
dc.type.statusPublisher version (final published refereed version)-
dc.author.emailemma.steel@stir.ac.uk-
dc.citation.date24/02/2016-
dc.contributor.affiliationPeter MacCallum Cancer Centre-
dc.contributor.affiliationUniversity of Melbourne-
dc.contributor.affiliationUniversity of Melbourne-
dc.contributor.affiliationUniversity of Melbourne-
dc.contributor.affiliationUniversity of Melbourne-
dc.contributor.affiliationUniversity of Melbourne-
dc.contributor.affiliationRoyal Women's Hospital (Victoria Australia)-
dc.contributor.affiliationUniversity of Sydney-
dc.contributor.affiliationPeter MacCallum Cancer Centre-
dc.contributor.affiliationUniversity of Melbourne-
dc.contributor.affiliationPeter MacCallum Cancer Centre-
dc.contributor.affiliationPeter MacCallum Cancer Centre-
dc.contributor.affiliationUniversity of Melbourne-
dc.contributor.affiliationQueen Mary University of London-
dc.contributor.affiliationPeter MacCallum Cancer Centre-
dc.contributor.affiliationUniversity of Melbourne-
dc.identifier.isi000372258800018-
Appears in Collections:Faculty of Health Sciences and Sport Journal Articles

Files in This Item:
File Description SizeFormat 
Collins-etal-BCRT-2016.pdf1.68 MBAdobe PDFView/Open


This item is protected by original copyright



Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

If you believe that any material held in STORRE infringes copyright, please contact library@stir.ac.uk providing details and we will remove the Work from public display in STORRE and investigate your claim.